BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, December 25, 2025
Home » Authors » Anette Breindl

Anette Breindl

Articles

ARTICLES

BioWorld MedTech’s Diagnostics Extra for Feb. 20, 2020

Feb. 20, 2020
By Meg Bryant and Anette Breindl
Keeping you up to date on recent developments in diagnostics, including: Detailed mapping of breast tumors sheds light on role of genetic variations; Leveraging AI in breast cancer diagnosis; T cell population is biomarker for β-cell function; Oligodendrocyte-neural connections not just about myelin.
Read More
DNA sequencing

Passengers, noncoding genome affect how cancers play out

Feb. 20, 2020
By Anette Breindl
Beyond every binary is a more complex reality. And so it is with driver and passenger mutations. The separation of tumor mutations into drivers and passengers underpins much progress in the development of targeted therapies. By looking at passenger mutations more carefully, though, researchers at Yale University have shown that passenger mutations, too, played a role in how tumors progressed.
Read More
Progression of alpha-synuclein pathology
The lysosome link

Strengthening lysosomes could head Parkinson’s off at the pass

Feb. 19, 2020
By Anette Breindl
Parkinson’s disease (PD) is a neurodegenerative disorder. But not just. And it may not start that way. There is increasing evidence that a-synuclein, the protein whose aggregates eventually destroy midbrain dopaminergic neurons in PD (and that are the cause of other diseases collectively known as the synucleinopathies), first aggregates “in enteric neurons, the neurons that control gastrointestinal function,” Collin Challis told BioWorld.
Read More

BioWorld MedTech’s Oncology Extra for Feb. 18, 2020

Feb. 18, 2020
By Mark McCarty and Anette Breindl
Keeping you up to date on recent developments in oncology, including: New approach to photothermal treatment beats biofilm problem; Origin story helps ovarian cancer prognosis; Sharper look yields new potential kinase target in ovarian cancer; Autophagy activation may prevent metastasis.
Read More

BioWorld MedTech’s Diagnostics Extra for Feb. 13, 2020

Feb. 13, 2020
By Meg Bryant and Anette Breindl
Keeping you up to date on recent developments in diagnostics, including: Creating a safer MRI contrast agent; Novel blood test for HPV-related head and neck cancer; More enhancers suggest more pathogenicity: study; Distinguishing real from backseat drivers.
Read More
Migraine illustration
The long and short of it

Prolactin could explain sex differences in pain syndromes

Feb. 12, 2020
By Anette Breindl
The hormone prolactin is known for and named after its role in breastfeeding. But that is far from its only role. There are more than 300 identified functions of prolactin, which is present in both men and women, though women have higher levels, and extremely high levels late in pregnancy and during breastfeeding. Now, scientists at the University of Arizona have identified another function of prolactin signaling.
Read More
Coronavirus microscopic model
Ebola, malaria, HIV, TCM

Researchers cast wide net for rapid-draw weapons in 2019-nCoV fight

Feb. 11, 2020
By Anette Breindl
At this very early point in the emerging 2019-nCoV outbreak, knowledge about the virus is insufficient to predict what shape that outbreak will ultimately take.
Read More
3D model of coronavirus spike

Not yet a pandemic, 2019-nCoV has echoes of MERS, SARS, flu

Feb. 11, 2020
By Anette Breindl
The drug screens prompted by the SARS and MERS outbreaks have been useful for quickly identifying drug candidates. But in terms of their epidemiology, “SARS and MERS were different from this coronavirus,” Allison McGeer explained at a Feb. 3 webinar by Evercore ISI.
Read More

BioWorld MedTech’s Oncology Extra for Feb. 11, 2020

Feb. 11, 2020
By Mark McCarty and Anette Breindl
Keeping you up to date on recent developments in oncology, including: Study bolsters case for maximal resection for glioblastoma; CD47 knockout improves antitumor vaccine; Distinguishing real from backseat drivers; Protons come to American state of Alabama.
Read More
EEG testing
Decoding depression

EEG signature can predict response to SSRIs

Feb. 10, 2020
By Anette Breindl
For depression, and other mental health disorders, the era of precision medicine has yet to arrive. Symptoms are “very poorly reflective of the underlying biology,” Amit Etkin told BioWorld. Depression can manifest through multiple different symptoms that differ both between and within cultures.
Read More
View All Articles by Anette Breindl

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Acute myeloid leukemia illustration

    Apollo’s APL-4098 shows potent antileukemic effects

    BioWorld Science
    Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing